Pacira Pharmaceuticals (PCRX) PT Lowered to $52 at Jefferies
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mail
Get Alerts PCRX Hot Sheet
Price: $36.42 +0.22%
Rating Summary:
9 Buy, 19 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 15
Rating Summary:
9 Buy, 19 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 15
Join SI Premium – FREE
Jefferies lowered its price target on Pacira Pharmaceuticals (NASDAQ: PCRX) to $52.00 (from $57.00) while maintaining a Buy rating following results.
Analyst David Steinberg trimmed FY17 Exparel revs by $8M to $283M to align with the midpoint of updated guidance.They also trim FY18-20 sales ests by 4-6%
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Freedom Broker Upgrades Goldman Sachs (GS) to Buy
- Third Coast Bancshares Inc (TCBX) PT Lowered to $54 at StoneX
- Tango Therapeutics Inc. (TNGX) PT Raised to $45 at Wedbush
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT ChangeRelated Entities
Jefferies & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
